title: Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides.
abstract: Most gene therapy strategies related to p53 concentrate on the restoration of the activity of mutant p53, as several observations indicate that tumors and cell lines having the mutant gene are resistant to chemotherapy. However, as there is also some evidence to the contrary, we studied the relationship of the p53 status to the cellular response of glioma cells that were exposed to cisplatin. At a concentration of 2.5 microg/ml (which is about half the peak pharmacological blood level reached during chemotherapy), U373MG glioma cells, which had a mutant p53 gene, were more sensitive to the drug as compared to U87MG glioma cells (with normal p53). The U373MG cells responded with apoptosis while U87MG cells responded with a G2-M arrest. In U87MG cells, blocking the p53 response by antisense oligonucleotides also sensitized the cells to 2.5 microg/ml cisplatin, and shifted the cellular response from arrest to caspase 3-mediated apoptosis. A sensitive, p53-independent, mechanism for chemotherapy-induced apoptosis suggests that, in some cases, p53 abrogation by gene therapy or small molecule-based strategies could be a viable therapeutic strategy.
authors.affiliation: Department of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029.
authors.forename: Kamal
authors.initials: K
authors.lastname: Datta
authors.forename: Preeti
authors.initials: P
authors.lastname: Shah
authors.forename: Tapasya
authors.initials: T
authors.lastname: Srivastava
authors.forename: Srinivas G
authors.initials: SG
authors.lastname: Mathur
authors.forename: Parthaprasad
authors.initials: P
authors.lastname: Chattopadhyay
authors.forename: Subrata
authors.initials: S
authors.lastname: Sinha
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017209:Apoptosis; D045744:Cell Line, Tumor; D002470:Cell Survival; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D016195:G2 Phase / Q000187:drug effects; D016158:Genes, p53; D005910:Glioma / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D009154:Mutation / Q000235:genetics; D020320:Oligoribonucleotides, Antisense / Q000494:pharmacology / Q000627:therapeutic use*; D016159:Tumor Suppressor Protein p53 / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D020320:Oligoribonucleotides, Antisense; D016159:Tumor Suppressor Protein p53; D002945:Cisplatin